Genmab — Juni 2019
-
Det er en yderst relevant artikel med flere væsentlige pointer i relation til at forstå den aktuelle markedsudvikling og kursmønstret i mange aktier.
-
-
Ærgeligt at artiklen er betalingsbelagt. Jeg har dog prøvet at sammenfatte hovedpointen med mit citat.
-
Spændende om vi lukker over 1232.
-
Ja vi har jo set en dejlig tendens de sidste dage

-
Bella1...der er nogen som vågner...og ikke ved hvorfor..:-D
-
should we see this new Dara Mono trial as a maintenance trial? Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive (DART4MM) https://clinicaltrials.gov/ct2/show/NCT03992170?term=daratumumab+OR+ofatumumab+OR+tisotumab+OR+Genmab+OR+arzerra+OR+duobody&lupd_s=06%2F19%2F2019&rank=1
-
Det bliver nok ikke i dag den lukker i dagens højeste.
-
Måske kun hvis den berømte/berygtede Maia sniger sig ind.....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind